# Bram Vanparys

> Bram Vanparys is a Series A investor at Gimv (Amsterdam) backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gimv](https://shizune.co/investors/profile/gimv)
- Location: Amsterdam, The Netherlands
- Total investments: 6
- Last investment: Jun 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://nl.linkedin.com/in/bramvanparys

Bram Vanparys is a Series A investor at Gimv in Amsterdam focused on Health Care and Biotechnology. Bram Vanparys, PhD, MBA, joined the previous biopharma fund in 2015 as Investment Director. Between 2010 and 2015, Bram was senior investment manager life sciences at PMV (Brussels, Belgium), where he built the biotech franchise. He was instrumental in the start-up, growth and exit of several biotech companies. Before PMV, Bram was biotech analystat KBC Private Equity and consultant at Deloitte. He holds a PhD in Biotechnology from the University of Ghent, Belgium and an MBA from Vlerick Business School, Belgium. Bram is based in Amsterdam.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 67% |
| Biotechnology | 4 | 67% |
| Pharmaceutical | 3 | 50% |
| Therapeutics | 2 | 33% |
| Biopharma | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series C | 2 | 33% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 17% |
| Belgium | 1 | 17% |
| Germany | 1 | 17% |
| Switzerland | 1 | 17% |
| The Netherlands | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $100M | Series C | Jun 13, 2022 |  |
| Anjarium Biosciences | Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address arange of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach. | $60.4M | Series A | Sep 15, 2021 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $52.7M | Series B | Dec 04, 2019 |  |
| iSTAR Medical | iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $43.9M | Series C | Sep 05, 2019 |  |
| IOmx Therapeutics | iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action.The Company was founded on the successful concept of cancerimmune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy. | $43.9M | Series A | Sep 20, 2016 |  |
| FF Pharma | FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibodyproduction or chronic inflammation, are a feature. | $4.2M | Series A | Jan 23, 2013 |  |

6 of 6 investments shown.

## Co-investors
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 3 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 3 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 2 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 2 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 2 deals together

## About Gimv

VC Fund · Antwerpen, Belgium

Gimv is a European investment company with over three decades of experience in private equity and venture capital.Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 85 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employover 28,000 professionals.As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.More information on Gimv can be found on [www.gimv.com].

5 contacts available at Gimv.

| Name | Title | Profile |
| --- | --- | --- |
| Andreas Jurgeit | Partner | https://shizune.co/investors/profile/andreas-jurgeit |
| Anne Caron | Partner | https://shizune.co/investors/profile/anne-caron |
| Arie Hooimeijer | Partner | https://shizune.co/investors/profile/arie-hooimeijer |
| Bram Vanparys | Partner | https://shizune.co/investors/profile/bram-vanparys |
| Clemence Robles | Principal | https://shizune.co/investors/profile/clemence-robles |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bram Vanparys invest in?

Bram Vanparys invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bram Vanparys last invest?

The most recent investment recorded for Bram Vanparys closed in Jun 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co